… cisplatin plus veliparib was superior to cisplatin plus placebo … for cisplatin plus placebo and
a HR of 0·57, the study had 80… if cisplatin plus veliparib was superior to cisplatin plus placebo …

… Another randomized study will evaluate the addition of veliparib to cisplatin and etoposide
combination in patients with extensive stage small-cell lung cancer (SCLC; NCT01642251). …

… SCLC in a phase I trial. We showed the combination of veliparib with platinum doublet of
cisplatin and etoposide (CE) to be safe and tolerable in a phase I trial. The current phase II …

… efficacy of cisplatin plus PARPi veliparib (Vel) or placebo (P) … 1 line of prior therapy were
treated with cisplatin (75mg/m2) plus … Non-BRCA-like group did not show benefit of veliparib for …

… monotherapy at 400 mg orally twice daily after a minimum of 4 cycles of cisplatin and
veliparib/placebo. Pharmacodynamics of PARP inhibition will not be evaluated; however, this …

… In the phase II part, patients were randomized to receive veliparib or placebo during …
carboplatin and paclitaxel with veliparib or placebo. The study was prematurely discontinued owing …

… in vitro clearly demonstrates that veliparib potentiates the activity of cisplatin and carboplatin
[… trapping in cisplatin-treated cells, this activity is evident at veliparib exposures sufficient for …

… 1/2 study of veliparib or placebo in combination with cisplatin and etoposide in patients with
ED-SCLC (E2511 study). The regimen was found to be tolerable, and the Phase 2 part of the …

… In an international, phase 3, placebo-controlled trial, we assessed the efficacy of veliparib
added to first-line induction chemotherapy with carboplatin and paclitaxel and continued as …

… In a randomized phase II trial of veliparib or placebo in combination with carboplatin and
paclitaxel (C and P) for advanced NSCLC, the most favored outcomes were observed in the …